Managed Healthcare Executive February 19, 2024
The Health and Human Services department could wind up overpaying (or possibly underpaying) for the drugs for which it is negotiating a “maximum fair price” for Medicare under the Inflation Reduction Act, argue experts at the USC Schaeffer Center for Health Policy and Economics. A fuller picture of rebates and net prices could help that from happening, they say.
The Department of Health and Human Services (HHS) has selected the first 10 drugs subject to Medicare price negotiation under the Inflation Drug Act (IRA), although they won’t go into effect till Jan. 1, 2026. But the negotiation process — some say it is not really a negotiation but price setting by the federal government — has started and the negotiated...
Today's Sponsors
Today's Sponsor